ETF Holdings Breakdown of BPMC

Stock NameBlueprint Medicines Corp
TickerBPMC(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS09627Y1091
LEI5299004CC60O9T5HVM83

News associated with BPMC

CANADA LIFE ASSURANCE Co Has $541,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
CANADA LIFE ASSURANCE Co lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 17.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,220 shares of the biotechnology company’s stock after selling 1,345 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-04-30 08:48:53
Needham & Company LLC Issues Pessimistic Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock Price
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $133.00 to $130.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 46.93% […] - 2025-04-30 05:46:52
Wells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Wells Fargo & Company MN reduced its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 38.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 40,732 shares of the biotechnology company’s stock after selling 25,925 shares during the period. Wells Fargo & Company MN’s holdings in Blueprint Medicines were worth $3,553,000 as […] - 2025-04-23 08:06:57
Barclays PLC Buys 17,931 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Barclays PLC raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.5% during the 4th quarter, HoldingsChannel reports. The firm owned 189,127 shares of the biotechnology company’s stock after purchasing an additional 17,931 shares during the quarter. Barclays PLC’s holdings in Blueprint Medicines were worth $16,494,000 as of its most […] - 2025-04-21 07:56:54
Blueprint Medicines Co. (NASDAQ:BPMC) Receives $124.95 Consensus Target Price from Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have issued a buy recommendation and one […] - 2025-04-18 08:02:50
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by ExodusPoint Capital Management LP
ExodusPoint Capital Management LP decreased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 25.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,512 shares of the biotechnology company’s stock after selling 871 shares during the period. ExodusPoint Capital Management LP’s […] - 2025-04-14 07:46:56
California Public Employees Retirement System Sells 24,735 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
California Public Employees Retirement System lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 24.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 78,450 shares of the biotechnology company’s stock after selling 24,735 shares during the quarter. California Public Employees Retirement System’s holdings in Blueprint Medicines were worth […] - 2025-04-08 08:18:56
Schroder Investment Management Group Sells 57,865 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Schroder Investment Management Group lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 60.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,434 shares of the biotechnology company’s stock after selling 57,865 shares during the quarter. Schroder Investment Management […] - 2025-04-06 08:30:53
JPMorgan Chase & Co. Sells 66,018 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
JPMorgan Chase & Co. cut its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 5.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,155,634 shares of the biotechnology company’s stock after selling 66,018 shares during the quarter. JPMorgan Chase & Co. […] - 2025-04-03 08:26:59
Corebridge Financial Inc. Trims Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)
Corebridge Financial Inc. trimmed its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 6.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 31,613 shares of the biotechnology company’s stock after selling 2,006 shares during the period. Corebridge Financial Inc.’s holdings in Blueprint Medicines were worth $2,757,000 at the end of the most […] - 2025-04-01 09:36:50
Vanguard Group Inc. Grows Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Vanguard Group Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 1.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,774,884 shares of the biotechnology company’s stock after buying an additional 91,450 shares during the period. […] - 2025-04-01 09:02:51
KLP Kapitalforvaltning AS Acquires Shares of 12,900 Blueprint Medicines Co. (NASDAQ:BPMC)
KLP Kapitalforvaltning AS acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $1,125,000. A number of other hedge funds […] - 2025-03-31 08:46:50
Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) Target Price at $124.95
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and […] - 2025-03-24 06:40:47
Zurcher Kantonalbank Zurich Cantonalbank Has $1.39 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 17.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,936 shares of the biotechnology company’s stock after acquiring an additional 2,323 shares during […] - 2025-03-19 08:59:00
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Analysts at Wolfe Research
Wolfe Research initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Blueprint Medicines from a […] - 2025-03-19 07:12:52
Raymond James Financial Inc. Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)
Raymond James Financial Inc. acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the fourth quarter, Holdings Channel reports. The fund acquired 241,966 shares of the biotechnology company’s stock, valued at approximately $21,104,000. A number of other hedge funds have also recently bought and sold shares of BPMC. Quarry […] - 2025-03-17 07:48:49
Bank of New York Mellon Corp Buys 7,101 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Bank of New York Mellon Corp increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 2.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 303,432 shares of the biotechnology company’s stock after acquiring an additional 7,101 shares during the period. Bank of New York Mellon Corp’s holdings […] - 2025-03-10 08:54:51
Scotiabank Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)
Scotiabank started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $150.00 price target on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. JPMorgan Chase & Co. boosted their […] - 2025-03-10 05:50:51
Blueprint Medicines (NASDAQ:BPMC) Cut to “Sell” at StockNews.com
StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a hold rating to a sell rating in a report published on Monday. Other equities analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday. […] - 2025-03-04 06:49:10
Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.83 Average Target Price from Analysts
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, twelve have given a buy recommendation and one […] - 2025-02-27 07:07:33
Ieq Capital LLC Invests $886,000 in Blueprint Medicines Co. (NASDAQ:BPMC)
Ieq Capital LLC purchased a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the 4th quarter, Holdings Channel reports. The fund purchased 10,163 shares of the biotechnology company’s stock, valued at approximately $886,000. A number of other institutional investors also recently bought and sold shares of BPMC. Wellington Management Group […] - 2025-02-26 08:56:57
Rhumbline Advisers Sells 1,318 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Rhumbline Advisers trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 1.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,531 shares of the biotechnology company’s stock after selling 1,318 shares during the period. Rhumbline Advisers’ holdings […] - 2025-02-26 08:18:58
Blueprint Medicines (NASDAQ:BPMC) Raised to “Hold” at StockNews.com
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Saturday. Other equities research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines […] - 2025-02-24 06:52:49
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by StockNews.com
StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a hold rating to a sell rating in a research report released on Friday. A number of other research firms have also issued reports on BPMC. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. JPMorgan […] - 2025-02-17 06:53:14

BPMC institutional holdings

The following institutional investment holdings of BPMC have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 41,819USD 4,130,044
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 7,075USD 698,727 -1.1%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 30,429USD 3,005,168
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 30,429USD 3,005,168 -1.1%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 142USD 14,024 -1.1%
2025-05-08 IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc)) 5,098USD 503,478 -1.1%
2025-05-08 IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc)) 1,053 -7.8%USD 103,994 -8.9%
Total =116,045 USD 11,460,603
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.